{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:31:45Z","timestamp":1791311505710,"version":"4.3.1"},"reference-count":438,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.crohns.2009.12.001","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T08:34:54Z","timestamp":1268901294000},"page":"221-256","source":"Crossref","is-referenced-by-count":85,"title":["A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease"],"prefix":"10.1093","volume":"4","author":[{"given":"W.","family":"Miehsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Novacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Vogelsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Knoflach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Petritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kapitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2009.12.001_bib1","first-page":"47","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"JCC"},{"key":"10.1016\/j.crohns.2009.12.001_bib2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical review","volume":"15","author":"Cassinotti","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's diseaese","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2009.12.001_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","article-title":"Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement","volume":"20","author":"Aarden","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.crohns.2009.12.001_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib7","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2006.03026.x","article-title":"Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions","volume":"24","author":"Duburque","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib11","first-page":"1307","article-title":"Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology","volume":"33","author":"Lequerr\u00e9","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2133.2008.08728.x","article-title":"Review and expert opinion on preventions and treatment of infliximab-realated infusion reactions","volume":"159","author":"Lecluse","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/rheumatology\/41.6.631","article-title":"Infliximab and leflunomide combination therapy in rheumatoid arthritis; an open-label study","volume":"41","author":"Kiely","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","article-title":"Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction","volume":"97","author":"Kugathasan","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib16","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib17","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","article-title":"Infliximab in the treatment of Crohn's disease: a user's guide for clinicians","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib18","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1055\/s-2004-813567","article-title":"Infliximab in the treatment of Crohn's disease \u2014 a practical approach","volume":"42","author":"Tilg","year":"2004","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium","volume":"11","author":"Jacobstein","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","article-title":"Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease","volume":"11","author":"Nancey","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune disease induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract res Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib24","first-page":"439","article-title":"Pustular psoriasis induced by infliximab","volume":"3","author":"Thurber","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1345\/aph.1C477","article-title":"Psoriasiform eruption induxed by infliximab","volume":"38","author":"Verea","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.crohns.2009.12.001_bib26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1346-8138.2007.00312.x","article-title":"Psoriasiform and pustular eruption induced by infliximab","volume":"34","author":"Takahashi","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ibd.20137","article-title":"Anaother paradox in Crohn\u00b4s disease: new onset of psoriasis in a patient receiving tumor necrosis factor alpha antagonist","volume":"13","author":"Angelucci","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definitive rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.crohns.2009.12.001_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor alpha inhibitor-induced psoriasis or psoriasiform exanthemata","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib31","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl.1","key":"10.1016\/j.crohns.2009.12.001_bib32","first-page":"A190","article-title":"Psoriasis and eczema skin lesions associated with TNF-blockade therapy in IBD: natural history and clinical characteristics","volume":"136","author":"Rahier","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib33","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib34","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.crohns.2009.12.001_bib35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gut.2008.163683","article-title":"Dermatological complications and safety of anti-TNF treatments","volume":"58","author":"Kerbleski","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib36","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00130832-200410000-00013","article-title":"The immunological and clinical spectrum of delayed drug-induced exanthems","volume":"4","author":"Lerch","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.crohns.2009.12.001_bib38","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1468-3083.2007.02480.x","article-title":"Urticarial vasculitis due to infliximab","volume":"22","author":"Goulao","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.crohns.2009.12.001_bib39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumtic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.rhu.0000239901.34561.5e","article-title":"Henoch-Sch\u00f6nlein purpura after etanercept therapy for psoriasis","volume":"12","author":"Lee","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jbspin.2005.04.004","article-title":"Cutaneous lymphocytic vasculitis during TNF alpha antagonist therapy for polyarthritis","volume":"73","author":"Wendling","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.crohns.2009.12.001_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-3083.2005.01570.x","article-title":"Immunology of cutaneous vasculitis associated with both etanercept and infliximab","volume":"61","author":"Srivastava","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.crohns.2009.12.001_bib43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune disease induecs by TNF-targeted therapies","volume":"22","author":"Ramos- Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib44","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.crohns.2009.12.001_bib45","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.crohns.2009.12.001_bib46","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases","volume":"21","author":"Meiss","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.crohns.2009.12.001_bib47","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/ard.2007.078857","article-title":"Erythema multiforme with tumour necrosis factor inhibitors: a class effect?","volume":"67","author":"Kain","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib48","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/ACI.0b013e328216f54a","article-title":"Severe cutaneous adverse reactions to drugs","volume":"7","author":"Chia","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.crohns.2009.12.001_bib49","series-title":"Litt's drug eruption reference manual","first-page":"329","year":"2009"},{"key":"10.1016\/j.crohns.2009.12.001_bib50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000069965","article-title":"Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy","volume":"206","author":"Devos","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.crohns.2009.12.001_bib52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","article-title":"Infections associated with tumor necrosis factor-alpha antagonists","volume":"84","author":"Crum","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.crohns.2009.12.001_bib53","doi-asserted-by":"crossref","first-page":"i.v.29","DOI":"10.1136\/ard.2005.042390","article-title":"Update on tuberculosis and other opportunistic infections associated with drugs blocking tumor necrosis factor \u03b1","volume":"64","author":"Winthrop","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib54","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib55","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","article-title":"Infections associated with tumor necrosis factor-alpha antagonists","volume":"25","author":"Rychly","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.crohns.2009.12.001_bib56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib57","first-page":"217","article-title":"Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature","volume":"69","author":"Stas","year":"2006","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.crohns.2009.12.001_bib58","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2169\/internalmedicine.45.1623","article-title":"Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis","volume":"45","author":"Imaizumi","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib59","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/art.20973","article-title":"Development of fatal tuberculosis in a patient with rheumatoid arthritis after three years of treatment with infliximab: comment on the article by Wolfe et al.","volume":"52","author":"Molenaar","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib60","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0016-5107(04)02641-0","article-title":"Diagnosis by EUS trucut biopsy of extrapulmonary tuberculosis in a patient with Crohn's disease treated with infliximab","volume":"61","author":"Gleeson","year":"2005","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.crohns.2009.12.001_bib61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00054725-200501000-00017","article-title":"Unusual presentation of tuberculosis after infliximab therapy","volume":"11","author":"Magro","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib62","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4081\/monaldi.2004.712","article-title":"Difficult diagnosis of infliximab-related miliary tuberculosis","volume":"61","author":"Contini","year":"2004","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00054725-200407000-00018","article-title":"Colonic sarcoidosis, infliximab, and tuberculosis: a cautionary tale","volume":"10","author":"Sorrentino","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib64","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10067-004-0873-z","article-title":"Miliary tuberculosis after infliximab therapy in Lebanon","volume":"23","author":"Uthman","year":"2004","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib65","first-page":"1657","article-title":"Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid","volume":"30","author":"Parra Ruiz","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/030097402317255372","article-title":"Pulmonary miliary tuberculosis in a patient with anti-TNFalpha treatment","volume":"31","author":"Mayordomo","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib67","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0002-9343(01)01035-X","article-title":"Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor alpha inhibitor","volume":"112","author":"Wagner","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib68","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1572-0241.2001.03836.x","article-title":"Reactivation tuberculosis in a patient with anti-TNF-alpha treatment","volume":"96","author":"Nunez Martinez","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib69","first-page":"526","article-title":"Mycobacteria tuberculosis peritonitis associated with etanercept therapy [letter]","volume":"21","author":"Manadan","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"9556","key":"10.1016\/j.crohns.2009.12.001_bib71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(07)60078-6","article-title":"Disseminated tuberculosis after anti-TNFalpha treatment","volume":"369","author":"Malipeddi","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2009.12.001_bib72","first-page":"112","article-title":"Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment","volume":"63","author":"Efde","year":"2005","journal-title":"Neth J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0714.2006.00363.x","article-title":"Oral tuberculosis associated with a treatment with anti-rheumatic drugs","volume":"35","author":"Kolokotronis","year":"2006","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","article-title":"Tuberculosis and treatment with infliximab","volume":"346","author":"Keane","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib76","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib77","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib78","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib79","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib80","series-title":"Priorities for public health in Spain","first-page":"21","article-title":"SEPAS report: investing in health","year":"2002"},{"key":"10.1016\/j.crohns.2009.12.001_bib81","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib82","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib83","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib84","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cgh.2007.04.007","article-title":"Risk for active tuberculosis in inflammatory bowel disease patients","volume":"5","author":"Aberra","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib85","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk, and for managing M tuberculosis infection and disease in patients due to start anti-TNF alpha treatment","volume":"60","author":"Ormerod","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.crohns.2009.12.001_bib86","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/gut.2005.076034","article-title":"Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy","volume":"54","author":"Rampton","year":"2005","journal-title":"Gut"},{"issue":"Suppl. 2","key":"10.1016\/j.crohns.2009.12.001_bib87","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/ard.61.suppl_2.ii62","article-title":"Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biologic agents","volume":"61","author":"Furst","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib88","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"Pt 2","key":"10.1016\/j.crohns.2009.12.001_bib89","first-page":"S221","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"Mow","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib91","unstructured":"Long R, ed. Canadian Tuberculosis Standards, 5th edn. Canadian Lung Association, Health Canada, 2000."},{"key":"10.1016\/j.crohns.2009.12.001_bib92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1157\/13042212","article-title":"Consensus guidelines on tuberculosis and treatment of inflammatory bowel disease with infliximab","volume":"26","author":"Obrador","year":"2003","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib93","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib94","first-page":"474","article-title":"Infliximab does not suppress the tuberculin skin test (purified protein derivative)","volume":"34","author":"Hatemi","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib95","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.20496","article-title":"Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy","volume":"14","author":"Zabana","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib96","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2249.2007.03477.x","article-title":"Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease","volume":"150","author":"Clark","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.crohns.2009.12.001_bib97","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib98","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1183\/09031936.00017807","article-title":"Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6weeks following tuberculin skin testing","volume":"29","author":"Naseer","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.crohns.2009.12.001_bib99","first-page":"286","article-title":"Use of T-SPOT.TB in latent tuberculosis infection diagnosis in general and immunosuppressed populations","volume":"30","author":"Piana","year":"2007","journal-title":"New Microbiol"},{"key":"10.1016\/j.crohns.2009.12.001_bib100","doi-asserted-by":"crossref","first-page":"e2489","DOI":"10.1371\/journal.pone.0002489","article-title":"The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis","volume":"3","author":"Raby","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.crohns.2009.12.001_bib101","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-007-0361-2","article-title":"Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration","volume":"27","author":"Takahashi","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.crohns.2009.12.001_bib102","first-page":"49","article-title":"Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States","volume":"54","author":"Mazurek","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.crohns.2009.12.001_bib103","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib104","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent re-activation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arth Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib105","series-title":"Cochrane Library, Issue 2","first-page":"I","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane review)","author":"Smieja","year":"2004"},{"key":"10.1016\/j.crohns.2009.12.001_bib106","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib107","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-2006-926670","article-title":"Listeria meningitis in a patient with Crohn's disease\u2014a seldom, but clinically relevant adverse event of therapy with infliximab","volume":"44","author":"Dederichs","year":"2006","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib108","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2177\/jsci.29.160","article-title":"A case in which the subject was affected by Listeia meningoencephalitis during administration of infliximab for steroid-dependent adult onset Still's disease","volume":"29","author":"Yamamoto","year":"2006","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.crohns.2009.12.001_bib109","first-page":"60","article-title":"Listeria meningitis as complication of treatment with infliximab in a patient with Crohn's disease","volume":"98","author":"Osuna Molina","year":"2006","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.crohns.2009.12.001_bib110","first-page":"157","article-title":"Infliximab therapy in Crohn's disease complicated by Listeria monocytogenes meningoencephalitis","volume":"30","author":"Ramanampamonjy","year":"2006","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.crohns.2009.12.001_bib111","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ibd.20286","article-title":"Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease","volume":"14","author":"Izb\u00e9ki","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib112","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib113","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib114","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","article-title":"Tuberculosis and treatment with infliximab","volume":"346","author":"Zhang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(01)00945-7","article-title":"Reactivation of histoplasmosis after treatment with infliximab","volume":"112","author":"Nakelchik","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib116","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib117","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1503\/cmaj.1040563","article-title":"Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone","volume":"171","author":"Singh","year":"2004","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.crohns.2009.12.001_bib118","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib119","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/502250","article-title":"Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha\u2014 neutralizing antibody: a possible healthcare-associated case?","volume":"24","author":"De Rosa","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.crohns.2009.12.001_bib120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1157\/13062892","article-title":"Systemic candidiasis and infliximab therapy","volume":"27","author":"Belda","year":"2004","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib121","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib122","first-page":"606","article-title":"Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel","volume":"49","author":"Shrestha","year":"2004","journal-title":"Respir Care"},{"key":"10.1016\/j.crohns.2009.12.001_bib123","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00054725-200407000-00017","article-title":"Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease","volume":"10","author":"Seddik","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib124","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","article-title":"Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Velayos","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib126","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2009.12.001_bib127","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ibd.20536","article-title":"Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis","volume":"15","author":"Estrada","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib128","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infections in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib129","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: a meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib130","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib131","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib132","first-page":"621","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry","volume":"6","author":"Lichtenstein","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib133","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","article-title":"The safety-profile of anti-tumor necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up","volume":"29","author":"Lees","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib134","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2036.2009.04037.x","article-title":"Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections","volume":"30","author":"Schneeweiss","year":"2009","journal-title":"Aliment Phramacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib135","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.berh.2006.08.010","article-title":"Bacterial and opportunistic infections during anti-TNF therapy","volume":"20","author":"Strangfeld","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib136","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalisation for pneumonia","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthirits Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib137","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-\u03b1 antagonists","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/pmj.78.915.47","article-title":"Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis","volume":"78","author":"Chan","year":"2002","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.crohns.2009.12.001_bib139","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib140","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib141","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fitulizing Crohn's disease: results from the ACCENT II study","volume":"23","author":"Sands","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib142","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/01.MIB.0000172811.57242.18","article-title":"Use of endoscopic ultrasound guided combination medical and surgical therapy for patients with Crohn's perianal fistulas","volume":"11","author":"Schwartz","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib143","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2036.2003.01427.x","article-title":"Response of fistulating Crohn's disease to infliximab treatment assesses by magnetic resonance imaging","volume":"17","author":"Bell","year":"2003","journal-title":"Aliement Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib144","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00054725-200303000-00003","article-title":"Treatment of perianal fistulizing Crohn's disease with infliximab alone or as adjunct under anestesia with seton placement","volume":"9","author":"Regueiro","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00054725-200111000-00002","article-title":"Hepatitis B and C virus infection in Crohn's disease","volume":"7","author":"Biancone","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib146","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B. The natural and unnatural history of an immunological mediated liver disease","volume":"120","author":"Perillo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib147","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00535-008-2165-x","article-title":"Reactivation of hepatitis B in a patients with Crohn's disease treated using infliximab","volume":"43","author":"Ojiro","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib148","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib149","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V100.2.391","article-title":"Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus activation in hepatitis B virus surface antigen carriers","volume":"100","author":"Shibolet","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.crohns.2009.12.001_bib150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/08880010490273019","article-title":"Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with haematological malignancies: a preliminary report","volume":"21","author":"El-Sayed","year":"2004","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.crohns.2009.12.001_bib151","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ajh.20471","article-title":"Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy \u2014 a prospective case series","volume":"80","author":"Vassiliadis","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.crohns.2009.12.001_bib152","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib153","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib154","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","article-title":"Safety of anti-TNF-\u03b1 therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis","volume":"45","author":"Roux","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib155","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib156","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib157","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/ibd.20202","article-title":"Lamivudine resistance and exacerbation of Hepatitis B in infliximab-treated Crohn's disease","volume":"13","author":"Esteve","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib158","first-page":"77","article-title":"Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors","volume":"24","author":"Longo","year":"2000","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.crohns.2009.12.001_bib159","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumor necrosis factor \u03b1 antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib160","first-page":"1944","article-title":"Safety of anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection","volume":"35","author":"Ferri","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib161","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00042737-200102000-00016","article-title":"Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection","volume":"13","author":"Campbell","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.crohns.2009.12.001_bib162","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.crohns.2009.12.001_bib163","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/gast.2002.31602","article-title":"Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection","volume":"122","author":"Biancone","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib164","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1572-0241.2003.07245.x","article-title":"Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF","volume":"98","author":"Holtmann","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib165","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib166","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","article-title":"Hepatitis B and C virus infections and anti-tumor necrosis factor-\u03b1 therapy: guidelines for clinical approach","volume":"21","author":"Nathan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib167","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-2277.2006.00416.x","article-title":"Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation","volume":"20","author":"Bakker","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.crohns.2009.12.001_bib168","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.1442","article-title":"Epstein\u2013Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas","volume":"201","author":"Wong","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.crohns.2009.12.001_bib169","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cgh.2006.05.024","article-title":"Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease","volume":"4","author":"Schwartz","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib170","first-page":"1859","article-title":"Epstein\u2013Barr virus-related lymphomas in patients with inflammatory bowel disease","volume":"149","author":"Juffermans","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.crohns.2009.12.001_bib171","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1080\/00365520500529629","article-title":"Rectal Epstein\u2013Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature","volume":"41","author":"Bai","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib172","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00054725-200407000-00015","article-title":"Epstein\u2013Barr virus-associated lymphoma in Crohn's disease","volume":"10","author":"Losco","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib173","first-page":"302","article-title":"A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factor (remicade) in severe pediatric Crohn's disease","volume":"39","author":"Cezard","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib174","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00054725-200403000-00004","article-title":"A Epstein\u2013Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy","volume":"10","author":"Reijasse","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib175","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ibd.20131","article-title":"Infliximab and the risk of latent viruses reactivation in active Crohn's disease","volume":"13","author":"Lavagna","year":"2007","journal-title":"Iflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib176","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib177","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0399-8320(06)73573-4","article-title":"Severe varicella infection during treatment with infliximab for Crohn's disease","volume":"30","author":"Tougeron","year":"2006","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.crohns.2009.12.001_bib178","first-page":"2517","article-title":"Disseminated primary varicella infection during infliximab treatment","volume":"31","author":"Vonkeman","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib179","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/j.1572-0241.2004.41389_7.x","article-title":"Disseminated primary varicella after initiation of infliximab for Crohn's disease","volume":"99","author":"Leung","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib180","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00134-003-1867-z","article-title":"Disseminated tuberculosis, pulmonary aspergilosis, and cutaneous herpes simplex infection in a patient with infliximab and methotrexate","volume":"29","author":"Van der Klooster","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib181","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1440-0960.2005.00170.x","article-title":"Pyoderma gangrenosum complicated by herpes simplex virus infection","volume":"46","author":"Tai","year":"2005","journal-title":"Australas J Dermatol"},{"issue":"suppl2","key":"10.1016\/j.crohns.2009.12.001_bib182","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.028209","article-title":"Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection","volume":"63","author":"Calabrese","year":"2004","journal-title":"Annals Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib183","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/CMR.16.3.357-364.2003","article-title":"Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols","volume":"16","author":"Duchini","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.crohns.2009.12.001_bib184","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00007890-199703270-00008","article-title":"Routine immunization in adult renal transplant recipients","volume":"63","author":"Huzly","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.crohns.2009.12.001_bib185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.11.1.1","article-title":"Use of licensed vaccines for active immunization of the immunocompromised host","volume":"11","author":"Pirofski","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.crohns.2009.12.001_bib186","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007890-200208270-00020","article-title":"Efficacy and safety of immunization for pre- and post- liver transplant children","volume":"74","author":"Kano","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.crohns.2009.12.001_bib187","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0022-3476(05)81545-8","article-title":"Measles vaccination after orthoptic liver transplantation","volume":"123","author":"Rand","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.crohns.2009.12.001_bib188","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.bmt.1704878","article-title":"Early measles vaccination in bone marrow transplant recipients","volume":"35","author":"Machado","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.crohns.2009.12.001_bib189","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF00865476","article-title":"Attenuated varicella virus vaccine in children with renal transplants","volume":"8","author":"Zamora","year":"1994","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.crohns.2009.12.001_bib190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1399-3046.2005.00403.x","article-title":"Live virus immunization after orthotopic liver transplantation","volume":"10","author":"Khan","year":"2006","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.crohns.2009.12.001_bib191","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody response to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib192","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semarthrit.2003.10.003","article-title":"The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Elkayam","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib193","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib194","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF\u03b1 blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib195","first-page":"272","article-title":"Immune response following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib196","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2007.077552","article-title":"The effect of anti-tumor necrosis factor \u03b1 treatment on the antibody response to influenza vaccination","volume":"67","author":"Gelinck","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib197","article-title":"The effect of Infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","author":"Elkayam","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib198","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(82)90629-8","article-title":"Association of ulcerative colitis with multiple sclerosis","volume":"2","author":"Rang","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2009.12.001_bib199","doi-asserted-by":"crossref","first-page":"902","DOI":"10.4065\/75.8.802","article-title":"Concurrence of inflammatory bowel disease and multiple sclerosis","volume":"75","author":"Kimura","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.crohns.2009.12.001_bib200","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib201","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ibd.20406","article-title":"Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001\u20132002","volume":"14","author":"Cohen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib202","first-page":"304","article-title":"Occurrence of demyelinating diseases after anti-TNF\u03b1 treatment of inflammatory bowel disease: a Danish Crohn Colitis Database study","volume":"2","author":"Andersen","year":"2008","journal-title":"JCC"},{"issue":"Suppl II","key":"10.1016\/j.crohns.2009.12.001_bib203","first-page":"A57","article-title":"Concurrence of inflammatory bowel disease and multiple sclerosis. Clinical course and phenotypes","volume":"57","author":"Buzaglo","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib204","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumour necrosis factor therapy","volume":"20","author":"Desai","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib205","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med"},{"issue":"suppl. 1","key":"10.1016\/j.crohns.2009.12.001_bib206","first-page":"1121","article-title":"The role of TNF\u03b1 and lymphotoxin in demyelinating disease","volume":"58","author":"Lock","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib207","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"Van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.crohns.2009.12.001_bib208","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanism could tumor necrosis factor alpha antagonists improve arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib209","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib211","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","article-title":"Demyelinating during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Thomas","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.crohns.2009.12.001_bib213","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","article-title":"Serious adverse events with infliximab: analysis of spontaneously reported adverse events","volume":"5","author":"Hansen","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib214","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib215","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.optm.2005.07.003","article-title":"Acute inflammatory demyelinating optic neuritis: current concepts in diagnosis and management","volume":"76","author":"Bhatti","year":"2005","journal-title":"Optometry"},{"key":"10.1016\/j.crohns.2009.12.001_bib216","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-Tumor Necrosis Factor-(alpha) therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib217","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.122.5.793","article-title":"Infliximab-associated retrobulbar optic neuritis","volume":"122","author":"Mejico","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.crohns.2009.12.001_bib218","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w4","article-title":"Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease","volume":"140","author":"Strong","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib219","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1155\/2005\/358658","article-title":"Demyelination-like syndrome in Crohn's disease after infliximab therapy","volume":"19","author":"Freeman","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.mcg.0000155126.82171.32","article-title":"Association of anti-tumor necrosis therapy with the development of multiple sclerosis","volume":"39","author":"Enayati","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib221","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00042737-200605000-00021","article-title":"Neurological symptoms suggestive of demyelinating in Crohn's disease after infliximab therapy","volume":"18","author":"Dubenco","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib222","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/qjmed\/hcm060","article-title":"Infliximab-induced retrobulbar optic neuritis","volume":"100","author":"Mumoli","year":"2007","journal-title":"Q J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib223","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","article-title":"Approaches for identifying and defining environmentally associated rheumatic disorders","volume":"43","author":"Miller","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib224","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10067-005-0097-x","article-title":"New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients","volume":"25","author":"Tanno","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib225","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib226","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1572-0241.2006.00947.x","article-title":"Abnormal hepatic biochemistries in patients with inflammatory bowel disease","volume":"102","author":"Mendes","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib227","unstructured":"No name. Medical letter: Occurrence of hepatotoxicity and elevation of liver enzymes in patients treated with Remicade\u00ae (infliximab). Centocor (update 09.11.2007)."},{"key":"10.1016\/j.crohns.2009.12.001_bib228","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2009.12.001_bib229","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate or without concomitant infliximab: results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib230","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, plazebo-controlled trial. (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib231","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib232","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2009.12.001_bib233","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","article-title":"Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis","volume":"64","author":"Germano","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib234","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","article-title":"Infliximab-associated reversible cholestatic liver disease","volume":"76","author":"Menghini","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.crohns.2009.12.001_bib235","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/00044011-200626110-00008","article-title":"Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis","volume":"26","author":"Ierardi","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.crohns.2009.12.001_bib236","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-006-0253-y","article-title":"Successful treatment with etanecept in a patient with hepatotoxicity closely related to infliximab","volume":"26","author":"Garc\u00eda Aparicio","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib237","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib238","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/ibd.20230","article-title":"Occurrence of hepatoxicity and elevated liver enzymes in a Crohn's disease patient treated with infliximab","volume":"13","author":"Moum","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib239","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","article-title":"Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis","volume":"187","author":"Ozorio","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.crohns.2009.12.001_bib240","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","article-title":"Infliximab-induced hepatitis: absence of cross-toxicity with etanercept","volume":"75","author":"Thi\u00e9fin","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.crohns.2009.12.001_bib241","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2133.2006.07316.x","article-title":"Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study","volume":"155","author":"Smith","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib242","doi-asserted-by":"crossref","first-page":"A526","DOI":"10.1016\/S0016-5085(03)82662-8","article-title":"Improvement of liver function tests in patients with primary sclerosing cholangitis and Crohn's disease treated with infliximab","volume":"124","author":"Regueiro","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib243","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib244","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1572-0241.2006.01018.x","article-title":"Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systemic review and meta-analysis","volume":"102","author":"Dorn","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib245","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Embrel, etanecerpt) in patients with advanced heart failure","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.crohns.2009.12.001_bib246","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.crohns.2009.12.001_bib247","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.crohns.2009.12.001_bib248","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1 in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.crohns.2009.12.001_bib249","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Int Med"},{"issue":"Suppl 1","key":"10.1016\/j.crohns.2009.12.001_bib250","first-page":"SAT0456","article-title":"Review of anti-TNF agents safety data obtained from the Food and Drug Administration Freedom of Information Database","volume":"63","author":"Callegari","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.crohns.2009.12.001_bib251","first-page":"THU0301","article-title":"No increase in hepatic side effects or hospitalizations among RA patients using biologic treatment for rheumatoid arthritis patients","volume":"63","author":"Wolfe","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib252","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","article-title":"The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists","volume":"27","author":"Cole","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.crohns.2009.12.001_bib253","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","article-title":"Heart failure among younger rheumatoid arthritis and Crohn's Patients exposed to TNF-alpha antagonists","volume":"46","author":"Curtis","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib254","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibitor promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib255","first-page":"1958","article-title":"Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis","volume":"35","author":"Lazzerini","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib256","unstructured":"Data on file (S_AE_63_D2, 2006), Centocor, Inc."},{"key":"10.1016\/j.crohns.2009.12.001_bib257","doi-asserted-by":"crossref","unstructured":"Data on file (ISS; pages 134-136, 2005), Centocor, Inc.","DOI":"10.1515\/9783110931471.bm"},{"key":"10.1016\/j.crohns.2009.12.001_bib258","unstructured":"Data on file (Protocol C0168T47; 2004), Centocor, Inc."},{"key":"10.1016\/j.crohns.2009.12.001_bib259","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyans","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080075","article-title":"Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German university hospital","volume":"70","author":"Seiderer","year":"2004","journal-title":"Digestion"},{"key":"10.1016\/j.crohns.2009.12.001_bib261","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/rheumatology\/key051","article-title":"Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab","volume":"42","author":"Marchesoni","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib262","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/rheumatology\/keg341","article-title":"Pancytopenia in a patient with scleroderma treated with infliximab","volume":"42","author":"Menon","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib263","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0755-4982(05)83984-3","article-title":"Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease","volume":"34","author":"Chauveau","year":"2005","journal-title":"Presse Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib264","doi-asserted-by":"crossref","first-page":"E238","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4","article-title":"Severe neutropenia and thrombocytopenia associated with infliximab","volume":"139","author":"Vidal","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib265","first-page":"328","article-title":"Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis","volume":"22","author":"Godinho","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib266","first-page":"247","article-title":"Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondylarthropathy","volume":"23","author":"Favalli","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib267","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10067-006-0229-y","article-title":"A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap\/rheumatoid arthritis","volume":"26","author":"Hamaguchi","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib268","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/00054725-200409000-00033","article-title":"Crohn's disease, infliximab and idiopathic thrombocytopenic purpura","volume":"10","author":"Selby","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib269","first-page":"451b","article-title":"Infliximab for the treatment of severe steroid-refractory acute graft-versus-host disease","volume":"102","author":"Patriarca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.crohns.2009.12.001_bib270","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/ard.2003.006775","article-title":"Treatment of refractory psoriatic arthritis with infliximab: a 12months observational study of 16 patients","volume":"63","author":"Feletar","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib271","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.2007.123547","article-title":"Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease","volume":"56","author":"Salar","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib272","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2009.12.001_bib273","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s10067-006-0415-y","article-title":"Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges","volume":"26","author":"Montan\u00e9","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib274","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/kel204","article-title":"TNF-alpha blocker-induced thrombocytopenia","volume":"45","author":"Pathare","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib275","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V99.6.2252","article-title":"Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study","volume":"99","author":"Steensma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.crohns.2009.12.001_bib276","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0889-857X(05)70211-8","article-title":"Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis","volume":"27","author":"Keystone","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.crohns.2009.12.001_bib277","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1600-0609.2003.00115.x","article-title":"Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor","volume":"71","author":"Kuruvilla","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.crohns.2009.12.001_bib278","doi-asserted-by":"crossref","first-page":"G653","DOI":"10.1152\/ajpgi.2000.279.4.G653","article-title":"Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models","volume":"279","author":"Pucilowska","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.crohns.2009.12.001_bib279","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00054725-200401000-00009","article-title":"Medical therapy for Crohn's disease strictures","volume":"10","author":"Van Assche","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib280","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00384-005-0739-0","article-title":"Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease","volume":"21","author":"Sorrentino","year":"2006","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib281","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000101563","article-title":"Fibrotic strictures and anti-TNF-\u03b1 therapy in Crohn's disease","volume":"75","author":"Sorrentino","year":"2007","journal-title":"Digestion"},{"key":"10.1016\/j.crohns.2009.12.001_bib282","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib283","doi-asserted-by":"crossref","first-page":"A569","DOI":"10.1016\/S0016-5085(00)84412-1","article-title":"Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of newly described complication","volume":"118","author":"Toy","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib284","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/j.1572-0241.2000.02675.x","article-title":"Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease","volume":"95","author":"Vasilopoulos","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1443-1661.2006.00566.x","article-title":"Clinical and endoscopic healing after infliximab treatment in patients with Crohn's disease","volume":"18","author":"Sou","year":"2006","journal-title":"Digestive Endoscopy"},{"issue":"9","key":"10.1016\/j.crohns.2009.12.001_bib286","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/S0002-9270(02)05259-0","article-title":"Infliximab treatment does not result in an increased risk of intestinal strictures or obstriction in Crohn's disease patients: ACCENT I study results","volume":"97","author":"Lichtenstein","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib287","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1572-0241.2006.00463.x","article-title":"Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease","volume":"101","author":"Lichtenstein","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib288","first-page":"2691","article-title":"Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease","volume":"94","author":"Lichtenstein","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib289","first-page":"A215","article-title":"Treatment of small bowel inflammatory stricturing Crohn's disease with infliximab: an open pilot study","volume":"130","author":"Louis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib290","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S0002-9270(02)05260-7","article-title":"Strictures and response to infliximab in Crohn's disease","volume":"97","author":"Weinberg","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib291","first-page":"A100","article-title":"Symptomatic luminal stricture underlies infliximab non-response in Crohn's disease (CD)","volume":"122","author":"Prajapati","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib292","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s10350-008-9241-4","article-title":"Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey","volume":"51","author":"Matsumoto","year":"2008","journal-title":"Dis Col Rectum"},{"key":"10.1016\/j.crohns.2009.12.001_bib293","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2003-36677","article-title":"Anti-TNF antibodies in the treatment of inflammatory intestinal stenosis in Crohn's disease","volume":"41","author":"Holtmann","year":"2003","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib294","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/01.MIB.0000191612.43584.94","article-title":"Successful infliximab therapy for a stricture caused by Crohn's disease","volume":"11","author":"Knapp","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib295","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3748\/wjg.14.1885","article-title":"Effect of infliximab on small bowel stenosis in patients with Crohn's disease","volume":"14","author":"Pallotta","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib296","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2036.2008.03887.x","article-title":"Infliximab treatment for symptomatic Crohn's disease strictures","volume":"29","author":"Pelletier","year":"2009","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.crohns.2009.12.001_bib297","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000117306","article-title":"Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far?","volume":"77","author":"Sorrentino","year":"2008","journal-title":"Digestion"},{"key":"10.1016\/j.crohns.2009.12.001_bib298","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib299","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib300","first-page":"608","article-title":"Immunomodulators and \u201con demand\u201d therapy with infliximab in Crohn's disease: clinical experience with 400 infusions","volume":"98","author":"Kinney","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib301","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1053\/j.gastro.2003.06.004","article-title":"Infliximab at 5years-tweaking the recipe for success?","volume":"125","author":"Cohen","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib302","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"Marhebian","year":"2009","journal-title":"Am J gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib303","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","article-title":"Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?","volume":"13","author":"Rosh","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib304","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: a meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib305","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ibd.20074","article-title":"5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease","volume":"13","author":"Terdiman","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib306","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0016-5085(92)90029-X","article-title":"Survival and causes of death in patients with inflammatory disease: a population-based study","volume":"103","author":"Ekbom","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib307","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.crohns.2009.12.001_bib308","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1365-2036.2001.01023.x","article-title":"Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment","volume":"15","author":"Aithal","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib309","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2005.02.004","article-title":"The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents","volume":"56","author":"Kwon","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.crohns.2009.12.001_bib310","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00002281-200405000-00014","article-title":"Rheumatoid arthritis and malignant lymphomas","volume":"16","author":"Baecklund","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib311","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7152","key":"10.1016\/j.crohns.2009.12.001_bib312","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.crohns.2009.12.001_bib313","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1345\/aph.1H219","article-title":"Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease","volume":"41","author":"Masunaga","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.crohns.2009.12.001_bib314","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"issue":"suppl.1","key":"10.1016\/j.crohns.2009.12.001_bib315","first-page":"A818","article-title":"Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD) : Interim results of the Cesame cohort","volume":"134","author":"Beaugerie","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib316","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib317","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.2005.075937","article-title":"Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study","volume":"55","author":"Biancone","year":"2006","journal-title":"Gut"},{"issue":"suppl.1","key":"10.1016\/j.crohns.2009.12.001_bib318","first-page":"M1134","article-title":"Newly diagnosed neoplasia in a cohort of Crohn's disease patients treated with infliximab: a 3years longer follow up from a multi-center matched pair study","volume":"134","author":"Biancone","year":"2008","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.crohns.2009.12.001_bib319","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib320","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/gast.2002.30328","article-title":"Epstein\u2013Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine","volume":"122","author":"Dayharsh","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib321","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cyto.2006.03.005","article-title":"Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein\u2013Barr virus","volume":"33","author":"Baran-Marszak","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.crohns.2009.12.001_bib322","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cgh.2006.05.020","article-title":"Risks and benefits of infliximab for the treatment of Crohn's disease","volume":"4","author":"Siegel","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib323","first-page":"18","article-title":"A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia","volume":"6","author":"Wiedenmann","year":"2008","journal-title":"J Support Oncol"},{"key":"10.1016\/j.crohns.2009.12.001_bib324","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9)","author":"Jatoi","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.crohns.2009.12.001_bib325","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","article-title":"Tumor necrosis factor \u03b1 as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose","volume":"25","author":"Harrison","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.crohns.2009.12.001_bib326","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/MLG.0b013e31815abf4c","article-title":"Temporal relationship between antitumor necrosis factor-alpha antibody therapy and recrudescence of head and neck squamous cell carcinoma","volume":"118","author":"Engel","year":"2008","journal-title":"Laryngoscope"},{"key":"10.1016\/j.crohns.2009.12.001_bib327","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.healun.2006.06.008","article-title":"Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006","volume":"25","author":"Mehra","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.crohns.2009.12.001_bib328","first-page":"3","article-title":"The evaluation of renal transplantation candidates: clinical practice guidelines","volume":"1","author":"Kasiske","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1016\/j.crohns.2009.12.001_bib329","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF03086123","article-title":"Guidelines for heart transplantation","volume":"16","author":"de Jonge","year":"2008","journal-title":"Neth Heart J"},{"key":"10.1016\/j.crohns.2009.12.001_bib330","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005176-200502000-00026","article-title":"Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease","volume":"40","author":"Thayu","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib331","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib332","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/gut.2008.163279","article-title":"Hepatosplenic T cell lymphoma in inflammatory bowel disease","volume":"57","author":"Shale","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib333","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MPG.0b013e3181957a11","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease; update","volume":"48","author":"Mackey","year":"2009","journal-title":"J Ped Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib334","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib335","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease","volume":"98","author":"Baldassano","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib336","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u00b4s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib337","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00005176-200305000-00007","article-title":"A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease","volume":"36","author":"Cezard","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib338","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn\u00b4s disease at a pediatric inflammatory bowel disease center","volume":"98","author":"Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib339","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00005176-200409000-00008","article-title":"Safety of infliximab treatment in pediatric patients with inflammatory bowel disease","volume":"39","author":"Friesen","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib340","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.mpg.0000189137.06151.33","article-title":"Infliximab dependency in a national cohort of children with Crohn\u00b4s disease","volume":"42","author":"Wewer","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib341","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00005176-200407000-00010","volume":"39","author":"De Ridder","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib342","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00005176-200407000-00004","article-title":"Infliximab: how to use in pediatric Crohn\u00b4s disease","volume":"39","author":"Ruemmele","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib343","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.MPG.0000154660.62359.FE","article-title":"Can we alter the natural history of Crohn\u00b4s disease in children?","volume":"40","author":"Hyams","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib344","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005176-200203000-00017","article-title":"Infliximab as a novel therapy for pediatric ulcerative colitis","volume":"34","author":"Mamula","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib345","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00005176-200403000-00013","article-title":"Infliximab in pediatric ulcerative colitis: two-year follow-up","volume":"38","author":"Mamula","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib346","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.MIB.0000160803.44449.a5","article-title":"Infliximab efficacy in pediatric ulcerative colitis","volume":"11","author":"Eidelwein","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib347","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1053\/j.gastro.2007.01.063","article-title":"Timing infliximab in pediatric Crohn`s disease","volume":"132","author":"Kirschner","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib348","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ibd.20845","article-title":"Long-term outcome of maintenance infliximab therapy in children with Crohn\u00b4s disease","volume":"15","author":"Hyams","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib349","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn\u00b4s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib350","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2036.2003.01411.x","article-title":"Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model","volume":"17","author":"Crandall","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib351","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.mpg.0000226369.31956.bf","volume":"43","author":"De Ridder","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2009.12.001_bib352","doi-asserted-by":"crossref","first-page":"695-296","DOI":"10.1093\/rheumatology\/keh562","article-title":"Survival and safety of treatment with infliximab in the elderly population","volume":"44","author":"Chevillotte-Maillard","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib353","doi-asserted-by":"crossref","first-page":"903-307","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.crohns.2009.12.001_bib354","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.33.9.1226","article-title":"Mortality from Crohn's disease in Leicestershire, 1972\u20131989: an epidemiological community based study","volume":"33","author":"Probert","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib355","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/0016-5085(93)91068-S","article-title":"Intestinal cancer risk and mortality in patients with Crohn's disease","volume":"105","author":"Munkholm","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib356","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/00365529609006413","article-title":"Mortality in patients with Crohn's disease","volume":"31","author":"Cottone","year":"1996","journal-title":"Scand. J Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib357","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.1996.v110.pm8613037","article-title":"Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study","volume":"110","author":"Persson","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib358","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0016-5085(98)70421-4","article-title":"Crohn's disease in Olmsted County, Minnesota, 1940\u20131993: incidence, prevalence, and survival","volume":"114","author":"Loftus","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib359","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/gut.42.2.175","article-title":"General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study","volume":"42","author":"Palli","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib360","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1572-0241.2001.03466.x","article-title":"Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England","volume":"96","author":"Farrokhyar","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib361","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/gast.2002.33632","article-title":"Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark","volume":"122","author":"Jess","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib362","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1053\/j.gastro.2003.09.029","article-title":"Mortality in inflammatory bowel disease: a population-based cohort study","volume":"125","author":"Card","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib363","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/gut.2003.031476","article-title":"Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978\u20132001","volume":"53","author":"Masala","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib364","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/gut.2005.072793","article-title":"Crohn's disease: increased mortality 10years after diagnosis in a Europe-wide population based cohort","volume":"55","author":"Wolters","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib365","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/gut.2005.079350","article-title":"Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940\u20132004","volume":"55","author":"Jess","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib366","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1445-5994.1982.tb02443.x","article-title":"Inflammatory bowel disease in Auckland, New Zealand","volume":"12","author":"Eason","year":"1982","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib367","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/BF01316511","article-title":"Mortality in patients with ulcerative colitis in Leicestershire, 1972\u20131989: an epidemiological study","volume":"38","author":"Probert","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2009.12.001_bib368","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00341210","article-title":"Incidence of colorectal cancer and all cause mortality in non-selected patients with ulcerative colitis and indeterminate colitis in Malmo, Sweden","volume":"10","author":"Stewenius","year":"1995","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib369","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1053\/j.gastro.2003.09.036","article-title":"Survival and cause-specific mortality in ulercative colitis: follow up of a population-based cohort in Copenhagen County","volume":"125","author":"Winter","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib370","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/gut.2006.101519","article-title":"Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10years after diagnosis","volume":"56","author":"H\u00f6ie","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib371","first-page":"428","article-title":"Suspected cases of severe side effects after infliximab (Remicade) in Germany","volume":"98","author":"Andus","year":"2003","journal-title":"Med Klin"},{"key":"10.1016\/j.crohns.2009.12.001_bib372","first-page":"7","article-title":"Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature","volume":"7","author":"Alderson","year":"2005","journal-title":"MedGenMed"},{"key":"10.1016\/j.crohns.2009.12.001_bib373","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00054725-200409000-00024","article-title":"Fatal staphylococcal sepsis in Crohn's disease after infliximab","volume":"10","author":"Herrlinger","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib374","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1023\/B:DDAS.0000042246.58984.98","article-title":"Pneumacystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn\u00b4s disease","volume":"49","author":"Kaur","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2009.12.001_bib375","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/gut.2006.093294","article-title":"Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease","volume":"55","author":"Quispel","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib376","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMcpc059035","article-title":"Case 8-2006 \u2014 a 71-year-old woman with Crohn's disease and altered mental status","volume":"354","author":"Podolsky","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2009.12.001_bib377","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004836-200109000-00022","article-title":"Mortality associated with infliximab","volume":"33","author":"Lankarani","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib378","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-8553(05)70056-X","article-title":"Epidemiology and natural course of inflammatory bowel disease","volume":"28","author":"Andres","year":"1999","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.crohns.2009.12.001_bib379","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/pgmj.62.726.269","article-title":"Male fertility in Crohn's disease","volume":"62","author":"Burnell","year":"1986","journal-title":"Postgrad Med j"},{"key":"10.1016\/j.crohns.2009.12.001_bib380","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/BF02051924","article-title":"Crohn's disease and pregnancy","volume":"33","author":"Woolfson","year":"1990","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.crohns.2009.12.001_bib381","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/gut.21.6.469","article-title":"Ulcerative colitis and pregnancy","volume":"21","author":"Willoughby","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib382","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/gast.2002.30345","article-title":"Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared to a population sample","volume":"122","author":"Olsen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib383","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10350-004-0570-7","article-title":"Female infertility after ileal pouch-anal anastomosis for ulcerative colitis","volume":"47","author":"Johnson","year":"2004","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.crohns.2009.12.001_bib384","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/gut.2005.090316","article-title":"Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis","volume":"55","author":"Waljee","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib385","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.25.1.52","article-title":"Crohn's disease and pregnancy","volume":"25","author":"Khosla","year":"1984","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib386","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00004836-198908000-00011","article-title":"Male infertility in inflammatory bowel disease","volume":"11","author":"Narendranathan","year":"1989","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib387","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1191\/096032700678815765","article-title":"Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody","volume":"19","author":"Treacy","year":"2000","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.crohns.2009.12.001_bib388","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib389","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.MIB.0000164023.10848.c4","article-title":"Infliximab and semen quality in men with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib390","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1210\/jc.86.9.4480","article-title":"TNFalpha down-regulates the Fas ligand and inhibits germ cell apoptosis in the human testis","volume":"86","author":"Pentikainen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.crohns.2009.12.001_bib391","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1530\/eje.0.1510629","article-title":"Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist","volume":"151","author":"Suominen","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.crohns.2009.12.001_bib392","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3899\/jrheum.080554","article-title":"Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab","volume":"36","author":"Paschou","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib393","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-0897.2007.00499.x","article-title":"Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system","volume":"58","author":"Martin","year":"2007","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.crohns.2009.12.001_bib394","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1440-1746.2003.02983.x","article-title":"Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody)","volume":"18","author":"Burt","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib395","first-page":"241","article-title":"The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy","volume":"30","author":"Chakravarty","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib396","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ncprheum0044","article-title":"A woman with rheumatoid arthritis whose condition did not improve during pregnancy","volume":"1","author":"Ostensen","year":"2005","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib397","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/kel400","article-title":"Pregnancy in rheumatology patients exposed to ant-tumour necrosis factor (TNF)-alpha therapy","volume":"46","author":"Roux","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.crohns.2009.12.001_bib398","first-page":"437","article-title":"Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease","volume":"38","author":"Tursi","year":"2006","journal-title":"Digest Liv Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib399","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.1572-0241.2001.03987.x","article-title":"Infliximab treatment and pregnancy outcome in active Crohn's disease patients","volume":"96","author":"Srinivasan","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib400","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1111\/j.1572-0241.2006.00961.x","article-title":"Drug therapy of inflammatory bowel disease in fertile women","volume":"101","author":"Kroser","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib401","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib402","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumour necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib403","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","article-title":"Placental transport of immunoglobulin G","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.crohns.2009.12.001_bib404","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","article-title":"Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn","volume":"4","author":"Vasiliauskas","year":"2006","journal-title":"Clin Gastroenterolo Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib405","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2006.02786.x","article-title":"Review article: infliximab therapy for inflammatory bowel disease\u2014seven years on","volume":"23","author":"Rutgeerts","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib406","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2036.2008.03648.x","article-title":"Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception","volume":"27","author":"O'Donnell","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.crohns.2009.12.001_bib407","first-page":"989","article-title":"Infliximab levels in breast-milk of a nursing Crohn's patient","volume":"96","author":"Peltier","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib408","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.3748\/wjg.14.3085","article-title":"Is infliximab safe to use while breastfeeding?","volume":"14","author":"Stengel","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib409","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","article-title":"Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery","volume":"43","author":"Kane","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib410","first-page":"A753","article-title":"Infliximab in breast milk","volume":"13","author":"Forger","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.crohns.2009.12.001_bib411","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1111\/j.1572-0241.2000.03363.x","article-title":"Infliximab in Crohn's disease: first anniversary clinical experience","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib412","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","article-title":"Clinical experience with infliximab therapy in 100 patients with Crohn's disease","volume":"95","author":"Farrell","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib413","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1046\/j.1365-2036.2001.01092.x","article-title":"Clinical use of Infliximab in Crohn's disease: the Edinburgh experience","volume":"15","author":"Arnott","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib414","first-page":"930","article-title":"Infliximab in severe steroid-refractory ulcerative colitis: a pilot study","volume":"113","author":"Kaser","year":"2001","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.crohns.2009.12.001_bib415","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib416","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1572-0241.2001.04039.x","article-title":"Infliximab for refractory ulcerative colitis","volume":"96","author":"Chey","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib417","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","article-title":"Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital","volume":"8","author":"Hommes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib418","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Belgian Group of Infliximab Expanded Access Program in Crohn's disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib419","first-page":"973","article-title":"Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab). Results of a multicentric and retrospective study","volume":"26","author":"Doubremelle","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.crohns.2009.12.001_bib420","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1590-8658(02)80038-X","article-title":"Infliximab in treatment of Crohn's disease: the Milan experience","volume":"34","author":"Ardizzone","year":"2002","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib421","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1572-0241.2002.06026.x","article-title":"Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis","volume":"97","author":"Su","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib422","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1590-8658(02)80205-5","article-title":"Infliximab for treatment of steroid-refractory ulcerative colitis","volume":"34","author":"Actis","year":"2002","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.crohns.2009.12.001_bib423","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.12.001_bib424","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.2003.01686.x","article-title":"Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study","volume":"18","author":"Gornet","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib425","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.meg.0000108355.41221.77","article-title":"Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up","volume":"16","author":"Wenzl","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib426","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00042737-200411000-00014","article-title":"Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study","volume":"16","author":"Ochsenkuhn","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib427","first-page":"231","article-title":"Infliximab in the treatment of steroid-dependent ulcerative colitis","volume":"8","author":"Armuzzi","year":"2004","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.crohns.2009.12.001_bib428","first-page":"235","article-title":"Infliximab in the treatment of severe ulcerative colitis: a follow-up study","volume":"8","author":"Kohn","year":"2004","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.crohns.2009.12.001_bib429","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4321\/S1130-01082004000200002","article-title":"Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis","volume":"96","author":"Bermejo","year":"2004","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.crohns.2009.12.001_bib430","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib431","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"L\u00e9mann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.12.001_bib432","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0399-8320(06)73161-X","article-title":"Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up","volume":"30","author":"Poupardin","year":"2006","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.crohns.2009.12.001_bib433","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3748\/wjg.v13.i39.5238","article-title":"Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up","volume":"13","author":"Caviglia","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.12.001_bib434","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2036.2007.03383.x","article-title":"A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis","volume":"26","author":"Lees","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib435","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2036.2007.03415.x","article-title":"Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up","volume":"26","author":"Kohn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib436","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-2036.2007.03300.x","article-title":"Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.12.001_bib437","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.cgh.2008.05.010","article-title":"Infliximab for inflammatory bowel disease in Denmark 1999\u20132005: clinical outcome and follow-up evaluation of malignancy and mortality","volume":"6","author":"Caspersen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.12.001_bib438","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/0002018-200831120-00009","article-title":"Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands","volume":"31","author":"Vries","year":"2008","journal-title":"Drug Saf"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609001445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609001445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/4\/3\/221\/1025018\/4-3-221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T05:38:04Z","timestamp":1711345084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2009.12.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":438,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1873994609001445"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2009.12.001","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}